Clinical trial on ibandronate in patients with tumor-associated hypercalcemia / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 739-741, 2004.
Article
in Zh
| WPRIM
| ID: wpr-254257
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>Ibandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia.</p><p><b>METHODS</b>An open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L.</p><p><b>RESULTS</b>There was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%.</p><p><b>CONCLUSION</b>Ibandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.</p>
Full text:
1
Index:
WPRIM
Main subject:
Pathology
/
Phosphorus
/
Pruritus
/
Blood
/
Bone Neoplasms
/
Breast Neoplasms
/
Drug Administration Schedule
/
Calcium
/
Bodily Secretions
/
Therapeutic Uses
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
Language:
Zh
Journal:
Chinese Journal of Oncology
Year:
2004
Type:
Article